SAVIMS

SAVIMS logo white
Menu

Resource Type

COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Resource Type, Treatment, Viral illnesses

Comprehensive Prevention Strategies Against COVID-19, Influenza, and RSV – SUMMARY

| | COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Resource Type, Treatment, Viral illnesses

Reference: FLCCC Alliance. (2023). I-PREVENT COVID, FLU AND RSV protection. Retrieved from www.flccc.net Summary: The I-PREVENT protocol is designed for healthcare workers, high-risk individuals, and those with co-morbidities to mitigate the risks of COVID-19, influenza, and RSV infections. Recommended interventions include antiseptic mouthwashes containing chlorhexidine, povidone-iodine, or cetylpyridinium chloride, and supplementation with Vitamin D, Vitamin […]

COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Other viral illnesses, Resource Type, Treatment, Viral illnesses

Preventative Protocols for COVID-19, Influenza, and RSV

| | COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Other viral illnesses, Resource Type, Treatment, Viral illnesses

Reference: I-PREVENT. (2023). COVID, Flu and RSV protection. Retrieved from [source link if applicable, otherwise remove this line] Summary: The I-PREVENT protocol offers strategies for the prevention of COVID-19, influenza, and RSV. It includes pre-exposure and post-exposure prevention measures, particularly aimed at high-risk groups and healthcare workers. The pre-exposure approach recommends the use of antiseptic

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Association of Guillain-Barré Syndrome with COVID-19 Vaccination

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Abara, W. E., Gee, J., Marquez, P., Woo, J., Myers, T. R., DeSantis, A., Baumblatt, J. A. G., Woo, E. J., Thompson, D., Nair, N., Su, J. R., Shimabukuro, T. T., & Shay, D. K. (2023). Reports of Guillain-Barré syndrome after COVID-19 vaccination in the United States. JAMA Network Open, 6(2), e2253845. https://doi.org/10.1001/jamanetworkopen.2022.53845 Summary:

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Estimation of Number Needed to Vaccinate Against COVID-19 Hospitalisation

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: UK Health Security Agency. (2023). Estimation of number needed to vaccinate to prevent a COVID-19 hospitalisation for primary vaccination, booster vaccination (3rd dose), autumn 2022 and spring 2023 booster for those newly in a risk group. Retrieved from [URL] Summary: The UK Health Security Agency’s report outlines the calculation of the number needed to

COVID-19, Covid-19 vaccines, Other viral illnesses, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Rethinking Next-Generation Vaccines for Respiratory Viruses

| | COVID-19, Covid-19 vaccines, Other viral illnesses, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: Morens, D. M., Taubenberger, J. K., & Fauci, A. S. (2023). Rethinking next-generation vaccines for coronaviruses, influenza viruses, and other respiratory viruses. Cell Host & Microbe, 31, 146-157. https://doi.org/10.1016/j.chom.2022.11.016 Summary: The article discusses the challenges in developing effective vaccines for respiratory viruses such as SARS-CoV-2 and influenza. These viruses often replicate rapidly in the

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other viral illnesses, Peer-reviewed evidence, Resource Type, Statistical evidence, Vaccines, Viral illnesses

Rethinking Vaccines for Respiratory Viruses

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other viral illnesses, Peer-reviewed evidence, Resource Type, Statistical evidence, Vaccines, Viral illnesses

Reference: Morens, D. M., Taubenberger, J. K., & Fauci, A. S. (2023). Rethinking next-generation vaccines for coronaviruses, influenza viruses, and other respiratory viruses. Cell Host & Microbe, 31, 146–157. https://doi.org/10.1016/j.chom.2022.11.016 Summary: The authors discuss the challenges in developing effective vaccines for respiratory viruses like influenza and SARS-CoV-2. They highlight that these viruses replicate rapidly in

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Circulating Spike Protein and Myocarditis Post-COVID-19 Vaccination

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Yonker, L. M., Swank, Z., Bartsch, Y. C., et al. (2023). Circulating spike protein detected in post–COVID-19 mRNA vaccine myocarditis. Circulation, 147, xxx–xxx. https://doi.org/10.1161/CIRCULATIONAHA.122.061025 Summary: This study investigates the immunological profiles of adolescents and young adults who developed myocarditis following mRNA COVID-19 vaccination. The research involved blood sampling from 16 patients hospitalised with myocarditis

COVID-19, Covid-19 vaccines, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine safety & adverse events, Vaccines, Viral illnesses

COVID Vaccine Safety: A Critical Analysis

| | COVID-19, Covid-19 vaccines, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Kirsch, S. (2023). What you need to know about COVID vaccine safety. COVID-19 Early Treatment Fund. Retrieved from [insert URL] Summary: In his article, Steve Kirsch argues that COVID vaccines may be more harmful than beneficial, suggesting that for every life saved by vaccination, two people may die due to vaccine-related complications, creating a

COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Understanding the Persistence of SARS-CoV-2 mRNA Vaccines in Human Tissues

| | COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Krauson, A. J., Casimero, F. V. C., Siddiquee, Z., & Stone, J. R. (2023). Duration of SARS-CoV-2 mRNA vaccine persistence and factors associated with cardiac involvement in recently vaccinated patients. npj Vaccines, 8, 141. https://doi.org/10.1038/s41541-023-00742-7 Summary: This study investigates the persistence of SARS-CoV-2 mRNA vaccines in human tissues, focusing on recently vaccinated patients. Autopsies

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Treatment, Vaccines, Viral illnesses

Overview of Clinical Trial NCT04368728: Examining RNA Vaccines Against COVID-19

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Treatment, Vaccines, Viral illnesses

Reference: Pfizer. (2023). NCT04368728 FDA Clinical Trial: C4591001. Retrieved from [link to the document] Summary: The clinical trial NCT04368728, with protocol number C4591001, aims to evaluate the safety, tolerability, immunogenicity, and efficacy of RNA vaccine candidates against COVID-19 in healthy individuals. The trial is structured in three phases, assessing different doses and age groups, with

Scroll to Top